ConductScience.org, home

Gene · 6751

SSTR1: somatostatin receptor 1

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. SSTR1: somatostatin receptor 1. Genes, record 6751. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6751

On this page

Gene

Symbol
SSTR1
HGNC
Name
somatostatin receptor 1
HGNC
NCBI Gene ID
6751
NCBI Gene
HGNC ID
HGNC:11330
HGNC
Ensembl
ENSG00000139874
NCBI Gene
Aliases
SRIF-2, SS-1-R, SS1-R, SS1R, SST1
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P30872Somatostatin receptor type 13914Ensembl, GeneID, HGNC

Source UniProt

Patents50

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1464914P30872Espacenet
JP 2025529142 A2025-09-044455P30872Espacenet
US 12371689 B22025-07-294455P30872Espacenet
JP 2025032204 A2025-03-1136506P30872Espacenet
EP 4461818 A22024-11-1336506P30872Espacenet
JP 2023058610 A2023-04-2536506P30872Espacenet
US 11541119 B22023-01-032P30872Espacenet
US 11446398 B22022-09-2082332P30872Espacenet
US 11400116 B22022-08-02927P30872Espacenet
JP 2022524081 A2022-04-27185303P30872Espacenet

1 to 10 of 50

See all 50 patents

Drugs8

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
LUTETIUM OXODOTREOTIDECHEMBL4302409Somatostatin receptor binding agentBINDING AGENTChEMBL
LUTETIUM OXODOTREOTIDE LU-177CHEMBL4297545Somatostatin receptor binding agentBINDING AGENTChEMBL
OCTREOTIDECHEMBL1680Somatostatin receptor agonistAGONISTChEMBL
OCTREOTIDE ACETATECHEMBL1200480Somatostatin receptor agonistAGONISTChEMBL
PASIREOTIDECHEMBL3349607Somatostatin receptor 1 agonistAGONISTChEMBL
PASIREOTIDE DIASPARTATECHEMBL5314380Somatostatin receptor 1 agonistAGONISTChEMBL
PASIREOTIDE PAMOATECHEMBL5314382Somatostatin receptor 1 agonistAGONISTChEMBL
SOMATOSTATINCHEMBL1823872Somatostatin receptor agonistAGONISTChEMBL

Trials335

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07595237LUTETIUM OXODOTREOTIDE LU-177EARLY_PHASE1ClinicalTrials.gov
NCT07583563OCTREOTIDEClinicalTrials.gov
NCT07537010LUTETIUM OXODOTREOTIDE LU-177PHASE1ClinicalTrials.gov
NCT07534371SOMATOSTATINClinicalTrials.gov
NCT07460908OCTREOTIDEClinicalTrials.gov
NCT07316686LUTETIUM OXODOTREOTIDE LU-177PHASE1ClinicalTrials.gov
NCT07304466SOMATOSTATINClinicalTrials.gov
NCT07252401SOMATOSTATINClinicalTrials.gov
NCT07229768LUTETIUM OXODOTREOTIDE LU-177EARLY_PHASE1ClinicalTrials.gov
NCT07189871LUTETIUM OXODOTREOTIDE LU-177PHASE1/PHASE2ClinicalTrials.gov

1 to 10 of 335

See all 335 trials

NIH grants421

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleSSTR1 papersNewest fiscal year
P30CA016672Cancer Center Support Grant62025
P30CA008748Cancer Center Support Grant42025
P20GM103446Delaware INBRE32025
P30CA086862Cancer Center Support Grant32025
P30DK084567Mayo Center for Cell Signaling in Gastroenterology32025
P30DK036836Diabetes Research Center22025
P30DK042086Center for Interdisciplinary Study of Inflammatory Intestinal DIsorders (C-IID)22025
T32CA121938UCSD Cancer Center Training Program in Drug Development22025
I01BX004371Hi-jacking the kynurenine pathway: A new therapeutic approach used to treat cisplatin resistant lung cancer that evades immune surveillance and proliferates with increased ROS levels12025
K12CA086913Paul Calabresi Award in Clinical Oncology Research12025

1 to 10 of 421Source NIH's project files

See all 421 nih grants

Papers1,195

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Octreotide-Mediated Co-Solubilization of Paclitaxel and Docetaxel: A Novel Targeted Formulation for Synergistic Anticancer Chemotherapy.Pharmaceutics202642797334PubTator, text miningPubMed
Predictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors.J Neuroendocrinol202642785810PubTator, text miningPubMed
Multi-omics integration unravels four molecular subgroups of corticotroph pituitary neuroendocrine tumours with distinct clinicopathological features.Nat Commun202642552318PubTator, text miningPubMed
Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1-5 and Therapeutic Implications in Neuroendocrine and Non-Neuroendocrine Malignancies.Int J Cancer202642400125PubTator, text miningPubMed
Uncovering G Protein-Coupled Receptors: Novel Targets and Biomarkers for Predicting Glioma Prognosis.Ann Clin Transl Neurol202642163039PubTator, text miningPubMed
Functional profiling of somatostatin receptors identifies somatostatin receptor subtype 2 as a vulnerability in Succinate Dehydrogenase SDHB-deficient pheochromocytomas and paragangliomas.Mol Biomed202641928014PubTator, text miningPubMed
Somatostatin and its analogs in the management of postoperative pancreatic fistulas: A comprehensive review.World J Gastrointest Surg202641809322PubTator, text miningPubMed
Distribution of Somatostatin and Its Receptors in the Intestinal Tract in Healthy Patients and Patients with Type 2 Diabetes.J Clin Endocrinol Metab202641379811PubTator, text miningPubMed
Altered somatostatin receptor 3 expression and functional dysregulation in tuberous sclerosis complex.Prog Neurobiol202641352576PubTator, text miningPubMed
Road traffic noise exposure and blood DNA methylation at birth and in childhood: An epigenome-wide meta-analysis.Environ Int202641352164PubTator, text miningPubMed

1 to 10 of 1,195

See all 1,195 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/6751

GET https://conductscience.org/api/genes/v1/6751/patents?page=2